Rational deployment of antimalarial drugs in Africa

Ahould first-line combination drugs be reserved for paediatric malaria cases?

Colin J. Sutherland, Hamza Babiker, Margaret J. MacKinnon, Lisa Ranford-Cartwright, Badria Babiker E L Sayed

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Artemisinin-based combination therapy is exerting novel selective pressure upon populations of Plasmodium falciparum across Africa. Levels of resistance to non-artemisinin partner drugs differ among parasite populations, and so the artemisinins are not uniformly protected from developing resistance, already present in South East Asia. Here, we consider strategies for prolonging the period of high level efficacy of combination therapy for two particular endemicities common in Africa. Under high intensity transmission, two alternating first-line combinations, ideally with antagonistic selective effects on the parasite genome, are advocated for paediatric malaria cases. This leaves second-line and other therapies for adult cases, and for intermittent preventive therapy. The drug portfolio would be selected to protect the "premier" combination regimen from selection for resistance, while maximising impact on severe disease and mortality in children. In endemic areas subject to low, seasonal transmission of Plasmodium falciparum, such a strategy may deliver little benefit, as children represent a minority of cases. Nevertheless, the deployment of other drug-based interventions in low transmission and highly seasonal areas, such as mass drug administration aimed to interrupt malaria transmission, or intermittent preventive therapy, does provide an opportunity to diversify drug pressure. We thus propose an integrated approach to drug deployment, which minimises direct selective pressure on parasite populations from any one drug component. This approach is suitable for qualitatively and quantitatively different burdens of malaria, and should be supported by a programme of routine surveillance for emerging resistance.

Original languageEnglish
Pages (from-to)1459-1468
Number of pages10
JournalParasitology
Volume138
Issue number12
DOIs
Publication statusPublished - 2011

Fingerprint

combination drug therapy
antimalarials
Antimalarials
Drug Combinations
malaria
Malaria
Pediatrics
drugs
Pharmaceutical Preparations
therapeutics
artemisinin
Parasites
Plasmodium falciparum
parasites
Artemisinins
Therapeutics
Child Mortality
Far East
Population Dynamics
South East Asia

Keywords

  • drug resistance
  • Malaria
  • rational therapeutics

ASJC Scopus subject areas

  • Parasitology
  • Animal Science and Zoology
  • Infectious Diseases
  • Medicine(all)

Cite this

Rational deployment of antimalarial drugs in Africa : Ahould first-line combination drugs be reserved for paediatric malaria cases? / Sutherland, Colin J.; Babiker, Hamza; MacKinnon, Margaret J.; Ranford-Cartwright, Lisa; Sayed, Badria Babiker E L.

In: Parasitology, Vol. 138, No. 12, 2011, p. 1459-1468.

Research output: Contribution to journalArticle

Sutherland, Colin J. ; Babiker, Hamza ; MacKinnon, Margaret J. ; Ranford-Cartwright, Lisa ; Sayed, Badria Babiker E L. / Rational deployment of antimalarial drugs in Africa : Ahould first-line combination drugs be reserved for paediatric malaria cases?. In: Parasitology. 2011 ; Vol. 138, No. 12. pp. 1459-1468.
@article{47b5f513ff33412891d1bff8b03e4da4,
title = "Rational deployment of antimalarial drugs in Africa: Ahould first-line combination drugs be reserved for paediatric malaria cases?",
abstract = "Artemisinin-based combination therapy is exerting novel selective pressure upon populations of Plasmodium falciparum across Africa. Levels of resistance to non-artemisinin partner drugs differ among parasite populations, and so the artemisinins are not uniformly protected from developing resistance, already present in South East Asia. Here, we consider strategies for prolonging the period of high level efficacy of combination therapy for two particular endemicities common in Africa. Under high intensity transmission, two alternating first-line combinations, ideally with antagonistic selective effects on the parasite genome, are advocated for paediatric malaria cases. This leaves second-line and other therapies for adult cases, and for intermittent preventive therapy. The drug portfolio would be selected to protect the {"}premier{"} combination regimen from selection for resistance, while maximising impact on severe disease and mortality in children. In endemic areas subject to low, seasonal transmission of Plasmodium falciparum, such a strategy may deliver little benefit, as children represent a minority of cases. Nevertheless, the deployment of other drug-based interventions in low transmission and highly seasonal areas, such as mass drug administration aimed to interrupt malaria transmission, or intermittent preventive therapy, does provide an opportunity to diversify drug pressure. We thus propose an integrated approach to drug deployment, which minimises direct selective pressure on parasite populations from any one drug component. This approach is suitable for qualitatively and quantitatively different burdens of malaria, and should be supported by a programme of routine surveillance for emerging resistance.",
keywords = "drug resistance, Malaria, rational therapeutics",
author = "Sutherland, {Colin J.} and Hamza Babiker and MacKinnon, {Margaret J.} and Lisa Ranford-Cartwright and Sayed, {Badria Babiker E L}",
year = "2011",
doi = "10.1017/S0031182011001144",
language = "English",
volume = "138",
pages = "1459--1468",
journal = "Parasitology",
issn = "0031-1820",
publisher = "Cambridge University Press",
number = "12",

}

TY - JOUR

T1 - Rational deployment of antimalarial drugs in Africa

T2 - Ahould first-line combination drugs be reserved for paediatric malaria cases?

AU - Sutherland, Colin J.

AU - Babiker, Hamza

AU - MacKinnon, Margaret J.

AU - Ranford-Cartwright, Lisa

AU - Sayed, Badria Babiker E L

PY - 2011

Y1 - 2011

N2 - Artemisinin-based combination therapy is exerting novel selective pressure upon populations of Plasmodium falciparum across Africa. Levels of resistance to non-artemisinin partner drugs differ among parasite populations, and so the artemisinins are not uniformly protected from developing resistance, already present in South East Asia. Here, we consider strategies for prolonging the period of high level efficacy of combination therapy for two particular endemicities common in Africa. Under high intensity transmission, two alternating first-line combinations, ideally with antagonistic selective effects on the parasite genome, are advocated for paediatric malaria cases. This leaves second-line and other therapies for adult cases, and for intermittent preventive therapy. The drug portfolio would be selected to protect the "premier" combination regimen from selection for resistance, while maximising impact on severe disease and mortality in children. In endemic areas subject to low, seasonal transmission of Plasmodium falciparum, such a strategy may deliver little benefit, as children represent a minority of cases. Nevertheless, the deployment of other drug-based interventions in low transmission and highly seasonal areas, such as mass drug administration aimed to interrupt malaria transmission, or intermittent preventive therapy, does provide an opportunity to diversify drug pressure. We thus propose an integrated approach to drug deployment, which minimises direct selective pressure on parasite populations from any one drug component. This approach is suitable for qualitatively and quantitatively different burdens of malaria, and should be supported by a programme of routine surveillance for emerging resistance.

AB - Artemisinin-based combination therapy is exerting novel selective pressure upon populations of Plasmodium falciparum across Africa. Levels of resistance to non-artemisinin partner drugs differ among parasite populations, and so the artemisinins are not uniformly protected from developing resistance, already present in South East Asia. Here, we consider strategies for prolonging the period of high level efficacy of combination therapy for two particular endemicities common in Africa. Under high intensity transmission, two alternating first-line combinations, ideally with antagonistic selective effects on the parasite genome, are advocated for paediatric malaria cases. This leaves second-line and other therapies for adult cases, and for intermittent preventive therapy. The drug portfolio would be selected to protect the "premier" combination regimen from selection for resistance, while maximising impact on severe disease and mortality in children. In endemic areas subject to low, seasonal transmission of Plasmodium falciparum, such a strategy may deliver little benefit, as children represent a minority of cases. Nevertheless, the deployment of other drug-based interventions in low transmission and highly seasonal areas, such as mass drug administration aimed to interrupt malaria transmission, or intermittent preventive therapy, does provide an opportunity to diversify drug pressure. We thus propose an integrated approach to drug deployment, which minimises direct selective pressure on parasite populations from any one drug component. This approach is suitable for qualitatively and quantitatively different burdens of malaria, and should be supported by a programme of routine surveillance for emerging resistance.

KW - drug resistance

KW - Malaria

KW - rational therapeutics

UR - http://www.scopus.com/inward/record.url?scp=84855698085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855698085&partnerID=8YFLogxK

U2 - 10.1017/S0031182011001144

DO - 10.1017/S0031182011001144

M3 - Article

VL - 138

SP - 1459

EP - 1468

JO - Parasitology

JF - Parasitology

SN - 0031-1820

IS - 12

ER -